Skip to content
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Contact us
follow up meee
Treatment Initiation
Algorithm for Asthma Treatment with Zerafil
"
*
" indicates required fields
Step
1
of
6
0%
1- Is the patient currently having an exacerbation?
*
YES
NO
In the past 4 weeks, has the patient had?
Daytime asthma symptoms more than twice a week?
*
YES
NO
Any night waking due to asthma?
*
YES
NO
Reliever needed for symptoms more than twice a week?
*
YES
NO
Any activity limitation due to asthma?
*
YES
NO
Hidden
Level of asthma _sum
Has the patient had exacerbations in the past year?
*
YES
NO
Result of skin prick or specific IgE test:
*
Positive
Negative
Not assessed
Clinical assurance of the attending physician that the patient's asthma is allergic with the presence of one of the following:
Asthma is clinically allergen-driven
Blood eosinophils ≥150/µl
FeNO ≥ 20 ppb
Sputum eosinophils ≥ 2%
Select one or more options from the list above to proceed, OR
*
None of the above
Hidden
Result_clinical
Before assuming asthma is non-type 2 consider repeating blood eosinophils and FeNO up to 3 times (e.g., when asthma worsens, before giving OCS, or at least 1-2 weeks after a course of OCS, or on the lowest possible OCS dose)
*
Type 2 inflammation was proven by repeating the tests
Asthma is non-type 2
